GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Incretin-based therapies outperform placebo for glycemic control and weight loss in type 2 diabetes
Newer diabetes drugs outperform for blood sugar and weight loss
This network meta-analysis of 15 incretin-based therapies (IBTs) indicates that tirzepatide, orforglipron, and semaglutide provide superior …
A large analysis finds that newer incretin-based drugs like tirzepatide and semaglutide beat placebo for blood sugar and weight loss in type…
Retatrutide Demonstrates Dose Dependent Glycemic Control and Weight Loss in Type 2 Diabetes
Trial shows retatrutide improves blood sugar and weight in diabetes
Phase 3 data reveals retatrutide significantly reduces HbA1c and body weight in adults with type 2 diabetes compared to placebo.
A new trial shows that retatrutide helps people with type 2 diabetes lower their blood sugar levels and lose significant body weight.